Mental health conditions and receipt of mental health care by illicit lysergic acid diethylamide (LSD) use status among young adults in the United States
Beth Han, Carlos Blanco, Emily B. Einstein, Wilson M. Compton
Addiction June 1, 2022 DOI: 10.1111/add.15789 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 69,916 |
| Population | US young adults ages 18 to 25 |
| Topics | LSD |
| Citations | 16 |
| Key findings | Young adults with past-year illicit LSD use have elevated prevalence of mental health conditions and are less likely to receive mental health care. |
Abstract
Aim: To examine prevalence of mental health conditions and receipt of mental health care (MHC) by illicit lysergic acid diethylamide (LSD) use status (past-year; lifetime without-past-year; never) among young adults.
Design: Cross-sectional, annual survey data from 2015 to 2019 National Surveys on Drug Use and Health (NSDUH).
Setting: United States.
Participants: A total of 69 916 NSDUH participants ages 18 to 25.
Measurements: Outcomes included past-year serious psychological distress (SPD), suicidal ideation, Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV major depressive episode (MDE), any mental illness, serious mental illness, receipt of mental health care (MHC, inpatient/outpatient or receipt of prescription medications), and number of days of being unable to work or attend normal activities because of mental health conditions.
Findings: Multivariable analyses found that compared with those who never used illicit LSD, adults with past-year illicit LSD use had greater risk of suicidal ideation (adjusted risk ratio [ARR] = 1.2, 95% CI = 1.06-1.41), SPD (ARR = 1.2, 95% CI = 1.04-1.28), MDE (ARR = 1.3, 95% CI = 1.17-1.52), and any/serious mental illness (ARRs = 1.2-1.3, 95% CI = 1.02-1.41) and reported missing more days because of mental health conditions (adjusted incidence rate ratio = 1.6, 95% CI = 1.31-1.86). Lifetime (without past-year) use showed similar, although less consistent, associations. Compared with those never using illicit LSD, adults with past-year use were less likely to receive prescription medications for MHC (ARR = 0.7, 95% CI = 0.60-0.84) and to receive overall MHC (ARR = 0.7, 95% CI= 0.64-0.84). Compared with those using in the past-year, adults with lifetime (without past-year) use were more likely to receive prescription medications for MHC (ARR = 1.2, 95% CI = 1.01-1.46) and receive overall MHC (ARR = 1.2, 95% CI = 1.03-1.45).
Conclusions: Young adults with past-year illicit lysergic acid diethylamide use have elevated prevalence of mental health conditions and are less likely to receive prescription medications for mental health care and overall mental health care. Regardless of past-year use status, young adults with lifetime illicit lysergic acid diethylamide use may benefit from mental illness prevention and interventions.
Comparable studies
Other cross-sectional and survey studies on LSD, most cited first.
Citations in the library
Cited by 13
- Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably? Psychedelic Medicine June 1, 2024
- Deepening our understanding of psychedelics by expanding psychedelic data collection in the United States National Survey on Drug Use and Health Journal of Psychopharmacology September 16, 2022
- LSD use in the United States: Examining user demographics and their evolution from 2015–2019 Journal of Psychedelic Studies February 1, 2024
- A Scoping Review of Research in Naturalistic Studies with Psychedelics. Journal of Psychoactive Drugs June 28, 2025
- Race and Gender Differences in the Moderating Relationship of Psychedelics on Stigma and Distress Psychedelic Medicine April 22, 2025
and 8 more in the library
Cites 4
- Global Street Food: la cocina de la calle Diseño interior 2009
- Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology March 1, 2015
- Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine Journal of Neuroscience November 30, 2020
- Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials Frontiers in Psychiatry January 21, 2020